Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for STAT3 Inhibitor TTI-109, Plans 2027 Trial
Key Insights
Tvardi Therapeutics (search) has selected ulcerative colitis (search) as the lead indication for its oral STAT3 (search) inhibitor TTI-109 following a Phase 1 healthy volunteer study that demonstrated broad immune cell modulation.
More than 70% of UC patients fail to achieve clinical remission with currently approved therapies, and TTI-109 is designed to target STAT3 (search) at the convergence point of multiple inflammatory pathways.
Phase 1 data showed up to 76% reduction in pathogenic Th17 subsets, up to 43% reduction in Tfh populations, and up to 71% decline in B cell subsets associated with colonic inflammation.
Tvardi Therapeutics (search), Inc. (NASDAQ: TVRD), a clinical-stage biopharmaceutical company, announced on July 30, 2026 that it has selected ulcerative colitis (search) (UC) as the initial disease indication for its next-generation STAT3 (search) inhibitor, TTI-109. The decision follows the successful completion of a Phase 1 healthy volunteer study in which TTI-109 demonstrated consistent modulation of multiple STAT3-driven immune cell populations implicated in UC pathology.
STAT3 (search) functions as a convergent node downstream of multiple signaling pathways involved in UC, integrating immune dysregulation, chronic inflammation, and tissue remodeling that leads to fibrosis. Tvardi's strategy positions TTI-109 as a single oral agent targeting the intersection of pathways that currently approved therapies address only individually.
"We believe a single oral agent acting at that convergence point has the potential to help patients who have not responded adequately to a biologic or JAK inhibitor," said Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi. "This is what led us to prioritize UC as our initial indication for TTI-109."
Phase 1 Data Supporting the UC Indication
The Phase 1 healthy volunteer study showed that TTI-109 successfully modulated Th17, T follicular helper (Tfh), and B cell populations — the same cell types known to expand with UC disease severity and infiltrate the inflamed colon. Further analysis across the active dose range revealed broad suppression of pathogenic Th17-associated immune populations, including up to 76% reduction in subsets associated with mucosal destruction and treatment-refractory UC. Tfh immune populations that drive mucosal B cell responses were reduced up to 43% in subsets associated with disease activity. Suppression extended to B cell immunity, including up to 71% decline in subsets associated with colonic inflammation.
These findings are supported by published clinical studies linking reductions in activated STAT3 (search) with higher rates of clinical remission across multiple UC therapeutic classes.
Unmet Need in Ulcerative Colitis (search)
More than 1.25 million patients are diagnosed with UC in the United States, representing an addressable market of approximately $3 billion in the U.S. and $9 billion globally. Currently approved therapies — including anti-TNF, anti-integrin, anti-IL-12/23, S1P, and JAK inhibitors — achieve placebo-adjusted clinical remission rates below 30%, and most are administered parenterally. More than 70% of patients do not achieve clinical remission with these treatments, which target individual upstream pathways.
JAK inhibitors carry a black box warning for major adverse cardiovascular events, mortality, thrombosis, serious infections, and malignancy. By contrast, across more than 400 subjects dosed to date, Tvardi's STAT3 (search) inhibitors have demonstrated a differentiated safety profile from JAK inhibitors. TTI-109 is administered orally without a loading dose, and in preclinical models of UC, achieved more than eight-fold greater drug concentration in target tissue relative to plasma.
Planned Clinical Development
Tvardi plans to initiate a study of TTI-109 in patients with moderate-to-severe UC in 2027, subject to clearance of an Investigational New Drug (IND) application and additional funding. The primary endpoint will be safety, and the secondary endpoint will be clinical remission at 12 weeks. Exploratory pharmacodynamic endpoints will include serum and tissue biomarkers and analysis of single nucleotide polymorphisms (SNPs).
KOL Webinar Scheduled
Tvardi will host a Key Opinion Leader webinar featuring Randy Longman, MD, PhD, Director of the Jill Roberts Center for IBD and Associate Professor of Medicine at Weill Cornell Medicine, on Wednesday, August 19, 2026, at 11:00 a.m. ET. During the event, Tvardi management will present new data supporting the therapeutic potential of TTI-109 in UC, while Dr. Longman will provide an overview of the evolving UC treatment landscape, remaining unmet needs, and the potential role of novel therapies.